StockData

Integra LifeSciences vs Orthofix Medical

IART and OFIX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IART and OFIX compare

Integra LifeSciences is the larger company, worth 3.9 times as much as Orthofix Medical ($1.1B against $277M).

Orthofix Medical grew revenue faster over the last twelve months (3.0% versus 0.84% for Integra LifeSciences).

Integra LifeSciences keeps more of each dollar of sales as profit, with a net margin of 0.79% compared with −7.4% at Orthofix Medical.

Integra LifeSciences scores higher on the StockData Score (9 against 7 for Orthofix Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIARTOFIX
Size and price
Market cap$1.1B$277M
Share price$13.98$6.80
Change, 1 year16.1%−54.7%
Change, 5 years−78.4%−78.3%
Beta (5Y)1.870.45
Employees3,7001,605
StockData Score
Total score9 (better)7
Valuation score3 (better)1
Growth score22
Performance score33
Health score11
Dividend score00
Valuation
P/E82.2×–
P/S0.7×0.3× (better)
P/B1.0×0.6× (better)
EV/EBITDA10.7× (better)28.9×
P/FCF12.7×–
FCF yield7.9% (better)−10.0%
Fair value$14.79–
Margin of safety5.5%–
Growth
Revenue growth (TTM)0.84%3.0% (better)
Revenue growth, 5Y average3.6%15.1% (better)
Profitability
Gross margin52.4%71.3% (better)
Operating margin4.4% (better)−4.7%
Net margin0.79% (better)−7.4%
FCF margin5.2% (better)−3.3%
Return on equity1.2% (better)−13.9%
Return on invested capital5.6% (better)−5.6%
Financial health
Debt / equity–0.52
Net debt / EBITDA–8.62
Interest coverage0.8×–
Current ratio3.62 (better)2.84
Altman Z-score1.28 (better)0.93
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions94.4%94.0%
Held by insiders3.4%25.1%
Insider net buying, 12 months$0$5.3M (better)
Short interest, % of float10.5%7.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.